| Bryden Considine, DO | |
|
2500 Ne Neff Rd, Bend, OR 97701-6015 | |
| (541) 706-5911 | |
| (541) 706-2645 |
| Full Name | Bryden Considine |
|---|---|
| Gender | Male |
| Speciality | Hematology/oncology |
| Experience | 10 Years |
| Location | 2500 Ne Neff Rd, Bend, Oregon |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356760839 | NPI | - | NPPES |
| 500792455 | Medicaid | OR |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | FC0059243 (Oregon) | Secondary |
| 207RH0003X | Internal Medicine - Hematology & Oncology | DO203086 (Oregon) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Charles Home Health Services | Bend, OR | Home health agency |
| St Charles Medical Center - Bend | Bend, OR | Hospital |
| Harney District Hospital | Burns, OR | Hospital |
| St Charles Prineville | Prineville, OR | Hospital |
| Blue Mountain Hospital | John day, OR | Hospital |
| St Charles Madras | Madras, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| St Charles Health System Inc | 8729111513 | 206 |
News Archive
Ardea Biosciences, Inc. announced that additional positive data from its Phase 2 program for RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, are being presented at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism (EULAR) in Rome, Italy. RDEA594, a first-in-class selective inhibitor of the URAT1 transporter, treats the underlying cause of gout by increasing the excretion of uric acid in order to bring the body's levels of uric acid into a normal range.
Bayer HealthCare and Health Alliance Medical Plans have entered into an outcomes-based contract for people with relapsing-remitting multiple sclerosis (MS) who are taking Betaseron (interferon beta-1b) to reduce the frequency of clinical exacerbations.
Memorial Sloan Kettering Cancer Center introduced a new, consumer-friendly web presence for www.mskcc.org (Memorial Sloan Kettering Cancer Center) and www.sloankettering.edu (Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center), featuring an innovative platform and on-demand navigation for patients, caregivers, researchers, healthcare professionals, and graduate students, among other core audiences.
AlloSource, one of the nation's largest providers of cartilage, cellular, bone, skin and soft-tissue allografts for use in surgical procedures and wound care to advance patient healing, will share early results of its fresh cartilage allograft, ProChondrix Cartilage Restoration Matrix during the International Cartilage Repair Society's 13th World Congress in Sorrento-Naples, Italy.
New research shows that loss of a gene called NFKBIA promotes the growth of glioblastoma multiforme, the most common and deadly form of brain cancer, and suggests that therapies that stabilize this gene may improve survival for certain glioblastoma patients.
› Verified 3 days ago
| Entity Name | Bend Memorial Clinic Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699827477 PECOS PAC ID: 7214936533 Enrollment ID: O20061215000022 |
News Archive
Ardea Biosciences, Inc. announced that additional positive data from its Phase 2 program for RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, are being presented at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism (EULAR) in Rome, Italy. RDEA594, a first-in-class selective inhibitor of the URAT1 transporter, treats the underlying cause of gout by increasing the excretion of uric acid in order to bring the body's levels of uric acid into a normal range.
Bayer HealthCare and Health Alliance Medical Plans have entered into an outcomes-based contract for people with relapsing-remitting multiple sclerosis (MS) who are taking Betaseron (interferon beta-1b) to reduce the frequency of clinical exacerbations.
Memorial Sloan Kettering Cancer Center introduced a new, consumer-friendly web presence for www.mskcc.org (Memorial Sloan Kettering Cancer Center) and www.sloankettering.edu (Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center), featuring an innovative platform and on-demand navigation for patients, caregivers, researchers, healthcare professionals, and graduate students, among other core audiences.
AlloSource, one of the nation's largest providers of cartilage, cellular, bone, skin and soft-tissue allografts for use in surgical procedures and wound care to advance patient healing, will share early results of its fresh cartilage allograft, ProChondrix Cartilage Restoration Matrix during the International Cartilage Repair Society's 13th World Congress in Sorrento-Naples, Italy.
New research shows that loss of a gene called NFKBIA promotes the growth of glioblastoma multiforme, the most common and deadly form of brain cancer, and suggests that therapies that stabilize this gene may improve survival for certain glioblastoma patients.
› Verified 3 days ago
| Entity Name | St Charles Health System Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023331303 PECOS PAC ID: 8729111513 Enrollment ID: O20100730000227 |
News Archive
Ardea Biosciences, Inc. announced that additional positive data from its Phase 2 program for RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, are being presented at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism (EULAR) in Rome, Italy. RDEA594, a first-in-class selective inhibitor of the URAT1 transporter, treats the underlying cause of gout by increasing the excretion of uric acid in order to bring the body's levels of uric acid into a normal range.
Bayer HealthCare and Health Alliance Medical Plans have entered into an outcomes-based contract for people with relapsing-remitting multiple sclerosis (MS) who are taking Betaseron (interferon beta-1b) to reduce the frequency of clinical exacerbations.
Memorial Sloan Kettering Cancer Center introduced a new, consumer-friendly web presence for www.mskcc.org (Memorial Sloan Kettering Cancer Center) and www.sloankettering.edu (Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center), featuring an innovative platform and on-demand navigation for patients, caregivers, researchers, healthcare professionals, and graduate students, among other core audiences.
AlloSource, one of the nation's largest providers of cartilage, cellular, bone, skin and soft-tissue allografts for use in surgical procedures and wound care to advance patient healing, will share early results of its fresh cartilage allograft, ProChondrix Cartilage Restoration Matrix during the International Cartilage Repair Society's 13th World Congress in Sorrento-Naples, Italy.
New research shows that loss of a gene called NFKBIA promotes the growth of glioblastoma multiforme, the most common and deadly form of brain cancer, and suggests that therapies that stabilize this gene may improve survival for certain glioblastoma patients.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Bryden Considine, DO Po Box 6048, Bend, OR 97708-6048 Ph: (541) 382-4900 | Bryden Considine, DO 2500 Ne Neff Rd, Bend, OR 97701-6015 Ph: (541) 706-5911 |
News Archive
Ardea Biosciences, Inc. announced that additional positive data from its Phase 2 program for RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, are being presented at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism (EULAR) in Rome, Italy. RDEA594, a first-in-class selective inhibitor of the URAT1 transporter, treats the underlying cause of gout by increasing the excretion of uric acid in order to bring the body's levels of uric acid into a normal range.
Bayer HealthCare and Health Alliance Medical Plans have entered into an outcomes-based contract for people with relapsing-remitting multiple sclerosis (MS) who are taking Betaseron (interferon beta-1b) to reduce the frequency of clinical exacerbations.
Memorial Sloan Kettering Cancer Center introduced a new, consumer-friendly web presence for www.mskcc.org (Memorial Sloan Kettering Cancer Center) and www.sloankettering.edu (Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center), featuring an innovative platform and on-demand navigation for patients, caregivers, researchers, healthcare professionals, and graduate students, among other core audiences.
AlloSource, one of the nation's largest providers of cartilage, cellular, bone, skin and soft-tissue allografts for use in surgical procedures and wound care to advance patient healing, will share early results of its fresh cartilage allograft, ProChondrix Cartilage Restoration Matrix during the International Cartilage Repair Society's 13th World Congress in Sorrento-Naples, Italy.
New research shows that loss of a gene called NFKBIA promotes the growth of glioblastoma multiforme, the most common and deadly form of brain cancer, and suggests that therapies that stabilize this gene may improve survival for certain glioblastoma patients.
› Verified 3 days ago
Alanna Mozena, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 2500 Ne Neff Rd, Bend, OR 97701 Phone: 541-706-6892 Fax: 541-706-6813 | |
Ashley Marie Twyman, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 2500 Ne Neff Rd, Bend, OR 97701 Phone: 541-706-6892 Fax: 541-706-6813 | |
Dr. Gilbert B. Lee, M.D. Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 1558 Sw Nancy Way, Bend, OR 97702 Phone: 541-312-8679 | |
Ms. Christine Marie Pierson, MD Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 2965 Ne Conners Ave, Ste 280, Bend, OR 97701 Phone: 541-323-4269 | |
Dr. Michael N Harris, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1501 Ne Medical Center Dr, Bend, OR 97701 Phone: 541-382-2811 | |
Gordon Jeremy Juriansz, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 2500 Ne Neff Rd, Bend, OR 97701 Phone: 541-706-6892 | |
Dr. Ronald Daniel Rosen, M.D. Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 918 Ne 5th St, Bend, OR 97701 Phone: 541-388-3804 Fax: 541-388-3856 |